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Bacterial drug resistance is emerging as one of the most significant challenges to human health. Antimicrobial peptides (AMPs), which are
produced by many tissues and cell types of invertebrates, insects, and humans, as part of their innate immune system, have attracted considerable
interest as alternative antibiotics. Interest in novel mimics of AMPs has increased greatly over the last few years. This report details a new AMP
mimic, based on phenylene ethynylene, with improved antimicrobial activity and selectivity. Screening against a large set of bacterial and other
organisms demonstrates broad spectrum antimicrobial activity including activity against antibiotic resistant bacterial like methicillin-resistant
Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) as well as activity against yeast (Candida albicans) and fungus
(Stachybotrys chartarum). Bacterial resistance development studies using Staphylococcus aureus show a rapid increase in MIC for conventional
antibiotics, ciprofloxacin and norfloxacin. In sharp contrast, no change in MIC was observed for the AMP mimic. Cytotoxicity experiments show
that the AMP mimic acts preferentially on microbes as opposed to mammalian red blood cells, 3T3 fibroblasts, and HEPG2 cells. In vivo
experiments determined the maximum tolerated dose (MTD) to be 10 mg/kg suggesting a therapeutic window is available. These studies indicate
that nonpeptidic amphiphilic AMP mimics could be developed as potential new treatments for antibiotic-resistant bacterial infections.
© 2006 Elsevier B.V. All rights reserved.Keywords: Magainin; Phenylene ethynylene; Foldamer; Antimicrobial; Antibiotic-resistant1. Introduction
Bacterial resistance and its rapid increase is a major concern
of global public health. Resistance development is an even
bigger problem since the bacterial resistance is often not
restricted to the specific antibiotic prescribed, but generally
extends to other compounds of the same class. Alarmingly,
methicillin-resistant Staphylococcus aureus (MRSA), methicil-
lin-resistant Staphylococcus epidermidis, vancomycin-resistant
enterococci (VRE), ampicillin-resistant Escherichia coli, and
even vancomycin-resistant Staphylococcus aureus (VRSA)
have emerged as common nosocomial infections [1–3].
Antimicrobial peptides (AMPs) operate via non-specific
mechanisms, targeting the bacterial cell membranes and other
macromolecules, unlike conventional antibiotics, and as a result
have shown a low potential for the emergence of bacterial⁎ Corresponding author.
E-mail address: tew@mail.pse.umass.edu (G.N. Tew).
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doi:10.1016/j.bbamem.2006.03.001resistant development [4]. This unique feature has resulted in
substantial research efforts directed toward the potential of
AMPs and their mimics as novel antimicrobial therapies. This
special issue covers much of the exciting current research in this
area.
Native AMPs with broad-spectrum antimicrobial properties
such as magainin, defensin, melittin, and thionins are small
host-defense peptides (typically, 20–40 residues) found in a
wide range of species, including plants, frogs, worms, and
humans [5,6]. They vary in size, length, sequence, and structure
from the α-helical (magainin and cecropin) to the β-sheet
(bactenecin and defensin) peptides which represent two major
classes of AMPs. Despite this large diversity, they adopt highly
amphiphilic topologies in which the hydrophilic and hydro-
phobic side chains segregate into distinctly opposing regions or
faces of the molecule. This is referred to as facially amphiphilic.
This unique amphiphilic topology and polycationic nature leads
to membrane insertion, eventually depolarizes the membrane
potential, disrupts membrane integrity, and ultimately kills the
microbe [7–9].
Table 1
Antibacterial activities of 1
Oligomer MIC (μg/mL)
MW S. aureus E. coli E. faecalis K. pneumoniae
1 575 0.2 0.1 0.2 1.56
2 875 3.13 25 12.5 >100
3 1155 12.5 50 25 >100
MSI-78 2478 12 12 – –
Table 2
MIC of 1 against a large panel of bacteria
Organism description Isolate
number
MIC a MIC a
1 Linezolid
Enterococcus faecium 1,162,827 8 2
Enterococcus faecium 1,162,828 8 2
Enterococcus faecium 1,162,826 0.5 2
Enterococcus faecium 1,162,818 0.5 4
Enterococcus faecium 1,162,819 0.5 8
Enterococcus faecium 1,162,820 0.5 2
Enterococcus faecalis 1,162,825 1 2
Enterococcus faecalis 1,162,836 1 2
Haemophilus influenzae 1,162,808 4 >8
Haemophilus influenzae 1,162,810 4 8
Stenotrophomonas (Xanthomonas)
maltophilia
1,162,814 1 >8
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a major challenge, especially when the target is the cell
membrane. However, AMPs have already evolved excellent cell
discrepancy so that learning to capture, or mimic, these essential
properties in non-native structures will lead to fundamental
understanding of this delicate and complicated process. Even
more importantly, these discoveries offer the potential to
develop novel agents to combat bacterial infections. This
would have a major positive impact on global health care. Over
the last decade, new classes of peptidic and nonpeptidic
antimicrobials with structures similar to that of cationic and
facially amphiphilic AMPs have been extensively investigated.
There have been a number of studies reporting non-native
antibiotics that follow the mechanism of natural AMP, such as
α-amino acids [10–12], β-amino acids [13–16], peptoids [17],
aromatic oligomers [18–20], and synthetic polymers [21–26].
We recently designed a series of polymeric phenylene
ethynylenes with both good activity and selectivity [26]. This
report demonstrated that abiotic structures, and even polymeric
materials, could be designed with antibacterial activity that is
non-hemolytic. Polymeric systems with average molecular
weight of 1600 Da had an MIC of 50 μg/mL and HC50 of
540 μg/mL compared to the potent magainin analog, MSI-78
[27–31], which had an MIC of 12.5 μg/mL and HC50 of
120 μg/mL. Although the polymeric analog was not quite as
potent as MSI-78, it was just a selective based on a comparison
of the HC50 and MIC values. This notion is now extended to
discrete, small oligomers with increased potency, better
selectivity, broad spectrum activity, and significantly decreased
bacterial resistance compared to ciprofloxacin and norfloxacin.
These results demonstrate that the phenylene ethynylene
oligomer has excellent biological activity and maybe a
promising candidate for potential treatment of antibiotic
resistant bacterial infections.
2. Results and discussion
2.1. Antibacterial activity
Based on our previous study of polymeric phenylene
ethynylene [26], a series of discrete smaller molecular weight
(MW) oligomers were prepared. This includes the three
structures shown in Fig. 1 that contain three (1), five (2), and
seven (3) aromatic rings, respectively. These oligomers haveFig. 1. Chemical structure of discrete, facially amphiphilic phenylene
ethynylene antimicrobial AMP mimics.MW ranging between 595 and 1155 Da. Antibacterial screening
against a small battery of both gram-positive and gram-negative
bacteria shows clearly that the short three ring oligomer, 1, is the
most potent (see Table 1). The MIC of 1 is below 0.2 μg/mL for
three of the four bacteria and reaches a maximum of 1.5 μg/mL
for K. pneumonia. This is significantly more potent than the
magainin derivative MSI-78. In contrast, the MIC of 2 and 3
was above 10 μg/mL, comparable to MSI-78, with only one
exception. These results agree with similar findings on
arylamide and arylurea oligomers recently reported in which
the three aromatic ring structure represents a maximum in
potency and selectivity [19,20]. The potency of 1 motivated
further characterization of its antibacterial activity.
Table 2 shows the antibacterial activity of 1 against a larger
panel of bacteria. In each case, two isolates per strain were used
to uncover any unexpected selectivity between isolates. The
MIC of 1 is generally between 0.5 and 4 μg/mL which
compares favorably with Linezolid, a member of theStenotrophomonas (Xanthomonas)
maltophilia
1,162,815 1 >8
Staphylococcus epidermidis 1,162,840 0.5 1
Staphylococcus epidermidis 1,162,846 0.5 1
Staphylococcus haemolyticus 1,162,842 0.5 1
Staphylococcus haemolyticus 1,162,841 0.5 1
Staphylococcus hominis 1,162,844 0.5 1
Staphylococcus hominis 1,162,838 1 1
Staphylococcus saprophyticus 1,162,798 0.5 2
Staphylococcus saprophyticus 1,162,834 0.25 1
Streptococcus pyogenes 1,162,822 4 1
Streptococcus pyogenes 1,162,823 2 1
Streptococcus pneumoniae 1,162,833 2 1
Streptococcus pneumoniae 1,162,832 2 1
a μg/mL.
Fig. 2. Susceptibility of S. aureus to develop resistance against two conventional
antibiotics, ciprofloxacin and norfloxacin, as well as 1.
1389G.N. Tew et al. / Biochimica et Biophysica Acta 1758 (2006) 1387–1392oxazolidinones antibiotics. As expected, the activity of 1 is
generally independent of the isolate with one exception, E.
faecium. A larger screening of this organism showed two
distinct MIC values of 8.0 and 0.5 μg/mL. Similar variation is
observed in the control antibiotic with MIC values ranging from
2 to 8 μg/mL. In all cases shown in Table 2, the MIC of 1 is
comparable to the control.
2.2. Activity against antibiotic-resistant bacteria
AMP mimic 1 was screened against a series of antibiotic-
resistant bacteria and the results are shown in Table 3. Potent
activity of 1 was demonstrated against antibiotic resistant S.
aureus, E. faecium, E. faecalis, and S. pneumoniae. This
includes potent activity against MRSA and VRE. Activity was
also measured against P. aeruginosa and showed variation of
the MIC of 4, 16 and 32 μg/mL against three isolates. The MIC
of AMPs is known to increase against P. aeruginosa and so
these higher MIC values for 1 are not unexpected; even the
control showed an increase in MIC. The ability of 1 to remain
potently active against a large series of antibiotic resistant
bacteria is extremely encouraging.
To further evaluate the prospect of 1 against antibiotic
resistance, experiments were performed to measure the
susceptibility of S. aureus to develop resistance against two
conventional antibiotics, ciprofloxacin and norfloxacin which
are members of the fluoroquinolones, as well as 1. These
experiments were performed by a serial passage of S. aureus
to sub-lethal concentrations of the three antibiotics, followed
by determination of the MIC values every 24 h period [32].
Fig. 2 shows that no significant change in the MIC is
observed for 1 over the entire time course of the experiment
in sharp contrast to the conventional antibiotics. In as little as
six exposures, the MIC for ciprofloxacin and norfloxacin
both increased. By the 16th passage, the MIC has increased
from 0.195 to >12 μg/ml for ciprofloxacin and from 0.78 to
>60 μg/ml for norfloxacin. These data demonstrate thatTable 3
Antimicrobial Activity of 1 against antibiotic resistant strains
Organism description Isolate
number
Antibiotic
resistance
MIC a MIC a
1 Linezolid
Staphylococcus aureus 1,162,847 OX-R 0.5 2
Staphylococcus aureus 1,162,848 OX-R 0.5 2
Staphylococcus aureus 1,162,849 OX-R 0.5 2
Enterococcus faecium 1,162,818 VAN-R 0.5 4
Enterococcus faecium 1,162,819 VAN-R 0.5 8
Enterococcus faecium 1,162,820 VAN-R 0.5 2
Enterococcus faecalis 1,162,824 VAN-R 1 1
Enterococcus faecalis 1,162,837 VAN-R 1 2
Enterococcus faecalis 1,162,835 VAN-R 1 1
Pseudomonas aeruginosa 1,162,811 MDR 32 >8
Pseudomonas aeruginosa 1,162,812 MDR 4 >8
Pseudomonas aeruginosa 1,162,813 MDR 16 >8
Streptococcus pneumoniae 1,162,829 PEN-R 2 0.5
Streptococcus pneumoniae 1,162,830 PEN-R 2 0.5
Streptococcus pneumoniae 1,162,831 PEN-R 1 1
a μg/mL.resistance development for 1 is more difficult compared to
these fluoroquinolones and suggests that the antibacterial
mechanism is likely different. Previous results demonstrated
that 1 acts on the cytoplasmic membrane of S. aureus using
the membrane potential-sensitive dye, 3, 5′-dipropylthiacar-
bocyanine DiSC3(5) [33]. In addition, experiments performed
on model liposomes demonstrated the ability of 1 to
preferentially cause leakage of 10 mol% phosphatidylgly-
cerol-phosphatidylethanolamine vesicles compared to 10 mol
% phosphatyl-L-serine-phosphatidylcholine vesicles [33].
These membrane studies along with the resistance data
presented above suggests that direct action on the bacterial
membrane is a likely mechanism of action [24,33,34]. The
broad activity against antibiotic resistant bacteria and lack of
increase in MIC compared to ciprofloxacin is encouraging
evidence for the development of AMP mimics as potential
new therapies for antibiotic-resistant bacterial infections.Table 4
Antimicrobial Activity of 1
Strain MIC/MFC (μg/mL)
1 Amphotericin
B
Fluconazole
A. viscosus 0.8 –
S. mutans 0.1 a – –
H. marina 0.1 – –
P. Haloplanktis 1.0 – –
Aspergillus fumigatus ATCC 204304 32/32 1/4 >32/>32
Aspergillus niger 4/16 0.5/2 >32/>32
Aureobasidium pullulans ATCC 11942 1/1 0.06/0.25 >32/>32
Chaetomium globosum ATCC 13835 0.5/8 0.06/1 0.25/0.25
Penicillium funiculosum ATCC 10446 1/2 0.06/8 4/>32
Trichoderma virens ATCC 13213 32/32 2/8 >128/>128
Trichophyton rubrum 2/2 0.5/0.5 32/32
Trichophyton mentagrophytes 2/4 0.5/1 32/>32
Stachybotrys chartarum ATCC 11695 2/2 2/2 >32/>32
Candida albicans ATCC 10231 1/2 0.25/1 0.5/1
Cryptococcus neoformansATCC 36556 1/1 0.25/0.25 32/32
a MIC determined in a biofilm.
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The excellent activity of 1 against the large panel of bacteria,
including antibiotic resistant strains, and limited resistance
induction encouraged us to screen for wider antimicrobial
activity. Table 4 shows the MIC values of 1 against a range of
microbes including marine bacteria, oral healthcare pathogens,
yeast, and fungi. The activity against bacteria remains in the
<1 μg/mL range including against S. mutans in biofilms. The
MIC against yeast and fungus increases slightly to 1–2 μg/mL
for most except C. globosum which is 0.5 μg/mL and A. niger
which is 4.0 μg/mL. Two fungi, A. fumigatus and T. virens,
show higher MIC values of 32 μg/mL; however, these show
corresponding MIC increases for the two controls, amphotericin
B and fluconazole. These results demonstrate that 1 is not only
active against bacteria but also against yeast and fungus.
Cell selectivity is one of the most difficult challenges in
antibiotic development, especially if the target of action is the
cytoplasmic membrane [4]. In order to determine the ability of 1
to differentiate between microorganisms and mammalian cells,
the EC50 for three different cell types was determined. Human
red blood cell (RBC) lysis, or hemolysis, is the most common
assay of selectivity for AMPs and their mimics. In addition to
this assay, 3T3 fibroblasts, and HEPG2 liver cells, were also
assayed for cytotoxicity. Table 5 compares the cytotoxicity of
these three cell lines and selectivity of 1. The selectivity value is
a conservative estimate since it compares MIC, or >90%
reduction, to EC50, or 50% reduction. The AMP mimic, 1, is
approximately six times more cytotoxic to 3T3 fibroblasts and
HEPG2 cells than RBCs. When comparing selectivity between
microbial cells and mammalian cells, good selectivity is ob-
served. For S. aureus, the selectivity is over 400 for RBCs aswell
as 60 and 70 for 3T3 fibroblasts and HEPG2 cells, respectively.
Compared to melittin and MSI-78, 1 is significantly less
cytotoxic. Selectivity for all MIC values can be determined.
For example, selectivity compared to MRSA and VRE (MIC
0.5 μg/mL) is 176, 24, and 28 for RBCs, 3T3s, and HEPG2s,
respectively. UsingC. albicans and S. chartarum as examples of
yeast and fungi, respectively, the selectivity is 88 and 44 for
RBCs and 12 and 6 for 3T3 fibroblasts.
The difference in cytotoxicity between RBCs and 3T3
fibroblasts suggested in vivo studies would be critical to
evaluate the therapeutic potential of 1. Before determining the
MTD for 1, assays were performed to determine the MIC in the
presence of serum and whole blood. In the presence of 40%
mouse serum, the MIC was observed to increase from
approximately 1 to 16 μg/mL. In contrast, experiments
performed in whole human blood showed no change in theTable 5
Cytotoxicity of 1
Compound MIC
(μg/mL)
Cytotoxity
(EC50 μg/mL)
Selectivity (EC50/MIC)
S. aureus RBCs 3T3 HepG2 RBCs 3T3 HepG2
1 0.21 88 12 14 440 60 70
Melittin 2* 2 4 1 1 2 0.5MIC and no change in the time needed to reach the MIC. Using
mouse models, the MTD for 1 was determined to be 10 mg/kg.
This value suggests a therapeutic window exists for 1.
3. Conclusions
The development of novel antibacterial agents is critically
important. Designing abiotic oligomers with distinct polar and
non-polar facers, similar to AMPs, is a powerful approach to
creating broadly active antimicrobial agents. A unique pheny-
lene ethynylene oligomer is reported here which shows activity
against bacterial, yeast, and fungus. Because it is a non-natural
backbone without amide or ester functionality, it will not under-
go proteolytic degradation from enzymes, like natural AMPs.
This oligomer is active against antibiotic-resistant bacteria and
shows a lower propensity toward developing resistance in S.
aureus than ciprofloxacin. Integrating the physiochemical
studies with in vivo activity is a significant challenge; however,
a deeper understanding of the molecular mechanismwill provide
critical clues to this problem. Bringing a variety of analytical
tools to this problem is sure to provide new, fundamental insight.
The broad spectrum activity, potency, and selectivity of 1
strongly suggest this structure is a promising AMP mimic.
4. Experimental section
4.1. Antimicrobial activity
This procedure is a modification of the standard broth micro-
dilution assay recommended by the National Committee for
Clinical Laboratory Standards (NCCLS) which has been
developed for determining in vitro antimicrobial activities of
cationic agents by Hancock et al. [32] Bacteria were grown in
Mueller–Hinton broth (MH broth) at 37 °C overnight, and the
bacterial growth was measured by turbidity as optical density at
λ=600 (OD600) using an Eppendorf BioPhotometer. After the
regrowth of bacteria (OD600=0.5–0.6), the suspension is diluted
to approximately 5×105 CFU/ml and inoculated into a polypro-
pylene (Costar) 96-well round bottom plate (90 μl volumes).
Solution containing DMSO without compound was prepared as
a negative control. Compound stock solutions are prepared in
DMSO and serial two-fold dilutions of compound are made in
0.01% acetic acid and 0.2% bovine serum albumin directly in the
wells of the polypropylene plate at 10 μL/well. DMSO concen-
trations should not exceed 1% in the assay. One set of control
wells includes broth-only samples with dilution buffer for testing
sterility and providing blank values for the assay readings.
Vehicle-control wells containing the bacterial suspension with
DMSO (no compound) are also included. The assay plate was
incubated at 37 °C for 18 h. The minimum inhibitory concentra-
tion was measured by observing the presence of cell growth,
defined by NCCLS as a ≥2 mm button or definite turbidity.
4.2. Resistance study
In brief, the first MIC determination of 1 and two antibiotics
(ciprofloxacin and norfloxacin) against S. aureus was
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wells at the concentration of one-half MIC were removed and
used to prepare the bacterial dilution (OD600=0.001) for the
next experiment. These bacteria solutions were then replated on
new 96 well plates with fresh dilutions of compound and the
two controls. After incubation at 37 °C overnight, the change of
MIC values was determined. This experiment was repeated each
day for 16 passages.
4.3. Cytotoxicity assays
4.3.1. Hemolytic activity
Compound stock solutions and control solutions were
prepared by the same procedure in the antimicrobial activity
assay. Fresh human red blood cells (RBCs) were obtained by
centrifuging a whole blood (3000 rpm, 10 min) and removing
the plasma and the white blood cells. The RBCs (1 mL) was
diluted with 9 mL of TBS buffer (10 mM Tris buffer, pH=7.0,
150 mM NaCl) and this suspension was further diluted by a
factor of 40 to give a RBC stock suspension (0.25% blood
cells). This RBC stock (120 μL), TBS buffer (15 μL) and the
compound stock solutions (15 μL) (or control solutions) were
added to a 200-μL centrifugation tube and incubated at 37 °C
for 1 h. The tube was centrifuged at 4000 rpm for 5 min.
Supernatant (30 μL) was diluted with TBS buffer (100 μL), and
OD414 of the solution was measured as hemoglobin concentra-
tion. Melittin was used as a positive control, and the most
concentrated sample (100 μg/mL) was used as a reference for
100% hemolysis. A control solution containing serially
decreasing amounts of DMSO without compound was used as
a reference for 0% hemolysis.
4.3.2. MTS cytotoxicity assay
This protocol is based on one included with the CellTiter
96® AQueous Assay Reagents (Promega, Madison, WI). The
assay measures the reduction of MTS to Formazan by dehydro-
genase enzymes found in metabolically active cells. 0.1 mL of
cells were pipetted into a 96-well polystyrene TC-treated plate
at 104 cells/well. This plate was incubated at 37 °C overnight in
a CO2 incubator for 18 h. The cells were washed once with
0.1 mL of assay media, or tissue culture media without the
serum. Then, 0.09 mL assay media was added to each well and
serial dilutions of drug were pipetted in 0.01 mL volumes; final
well volume is 0.1 mL. The plate was then incubated for 1 h and
the cells were washed with media containing serum. The MTS
and PMS solutions were thawed in a 37 °C water bath for
15 min before use. A fresh 0.1 mL of tissue culture media and
0.02 mL of MTS-PMS solution (2 mLMTS+0.1 mL PMS) was
added to each well and shaken gently by hand for 20 s. The plate
was then incubated from 2.5 (3T3 cells) to 4 (HepG2 cells) h.
Following the final incubation, the plate is gently shaken again
for 20 s and read at 490 nm in a microplate reader.
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